AN OPTIMIZATION AND CHARACTERIZATION OF CHITOSAN BASED NANOPARTICLES CONTAINING METHYLPREDNISOLONE USING BOX-BEHNKEN DESIGN FOR THE TREATMENT OF CROHN’S DISEASE
Preparation and Characterization of Methylprednisolone Nanoparticles using Box-Behnken Design
Objective: The present research was designed to produce methylprednisolone containing chitosan based nanoparticles using Box-Behnken Design (BBD) and Response Surface Methodology (RSM) for optimization.
Methods: Nanostructures were prepared using ionic gelation method with screened process parameters. According to the design, methylprednisolone chitosan based nanopaticles (MCSNPs) were optimized using factors like methylprednisolone concentration, stirring speed and temperature where as particle size, zeta potential and % encapsulation efficiency as responses. From the observed values of responses with confirmation location and desirability, the predicted values were found to be very close to the observed values.
Results: Observed values for the optimized formulation have a particle size of 243±2.33 nm with an encapsulation efficiency of 79.3±7.2%. Morphology of the particles using scanning electron microscopy reveals nearly spherical shaped particles. Methylprednisolone was released in-vitro in a sustained manner for about 24 hrs in simulated colonic fluid pH 7, pH 7.8 (Fasted state) and phosphate buffer pH 7.4, when compared to simulated colonic fluid at pH 6 (Fed state). Optimized MCSNPs followed Korsmeyer peppas kinetics with drug release mechanism as anomalous transport.
Conclusion: Application of Box-behnken design and Response Surface Methodology using Design Expert software was successfully employed in the optimization of methylprednisolone loaded chitosan based nanoparticles with high encapsulation efficiency.
This work is licensed under a Creative Commons Attribution 4.0 International License.